Holoprosencephaly 5 (HPE5) Cell Models for Research

Holoprosencephaly (HPE) is a rare congenital brain malformation with an estimated prevalence of 1 in 250 conceptions, but only 1 in 10,000 live births due to high fetal mortality. HPE5 is a subtype caused by mutations in the ZIC2 gene. The clinical spectrum ranges from severe alobar HPE (incompatible with life) to milder microform with facial dysmorphism. According to WHO, congenital anomalies account for significant infant mortality, and HPE is a leading cause of structural birth defects. The NCI does not track HPE as it is not a cancer, but the genetic insights from HPE research inform developmental biology and cancer pathways. Five-year survival is not applicable; instead, survival depends on severity, with severe cases often fatal in utero or shortly after birth. Risk factors include genetic mutations and environmental factors, but sporadic cases are common.

HPE5 is an ideal model for studying the Sonic Hedgehog (SHH) signaling pathway, which is crucial for brain development and is also dysregulated in several cancers. The ZIC2 gene encodes a zinc-finger transcription factor that regulates SHH expression. Research on HPE5 can reveal fundamental mechanisms of forebrain development, and the pathway's relevance to cancer makes it a valuable model for drug discovery. Public datasets, such as those from the Developmental Genotype-Tissue Expression (dGTEx) project and ClinVar, provide genomic and clinical data. Open questions include the precise molecular mechanisms of ZIC2 mutations and their differential effects on phenotype.

• • While HPE5 is not a cancer, the SHH pathway is a major oncogenic pathway in medulloblastoma and basal cell carcinoma. The pathway involves:
• • SHH ligand binding to PTCH1 receptor, relieving inhibition of SMO.
• • SMO activation leads to GLI transcription factor activation.
• • GLI proteins (GLI1, GLI2, GLI3) translocate to the nucleus and regulate target genes.
• • ZIC2 interacts with GLI proteins to modulate their activity.
• • Mutations in ZIC2 disrupt this regulation, leading to aberrant SHH signaling during development.

| Gene | Frequency (%) | Mutation Type | Functional Effect |

|------|---------------|---------------|-------------------|

| ZIC2 | ~5% of HPE cases | Nonsense, frameshift, missense | Loss of function, haploinsufficiency |

| SHH | ~5% | Missense, splice | Reduced ligand activity |

| SIX3 | ~3% | Missense, deletion | Impaired forebrain development |

| TGIF1 | ~2% | Missense, deletion | Disrupted TGF-beta signaling |

Data from ClinVar and COSMIC (for cancer relevance).

• • Key networks include:
• • SHH signaling: SHH, PTCH1, SMO, GLI1-3, ZIC2.
• • TGF-beta signaling: TGIF1, SMADs.
• • Notch signaling: involved in neurogenesis.
• • WNT signaling: cross-talk with SHH.
• • Bullet list of key nodes:
• • SHH ligand
• • PTCH1 receptor
• • SMO
• • GLI transcription factors
• • ZIC2
• • TGIF1

| Cell Line | Origin | Key Mutations |

|-----------|--------|---------------|

| SH-SY5Y | Neuroblastoma | MYCN amplification, TP53 wild-type |

| IMR-32 | Neuroblastoma | MYCN amplification |

| H9 hESC | Embryonic stem cell | Wild-type |

| Huh7 | Hepatocellular carcinoma | TP53 mutation |

Organoids derived from hESCs or iPSCs can model forebrain development and are useful for studying HPE5.

• • Zebrafish: Zic2 knockdown models show cyclopia.
• • Mouse: Zic2 knockout mice exhibit holoprosencephaly.
• • PDX models: not typical for HPE, but used for SHH-driven cancers.
• • GEMM: conditional knockouts of Zic2 in mice.

CRISPR-Cas9 gene editing enables creation of isogenic cell lines with specific ZIC2 mutations. For example, a ZIC2 knockout in SH-SY5Y cells can be generated to study loss-of-function effects. Alternatively, a knock-in of a pathogenic point mutation (e.g., p.Arg245Trp) can model a specific patient variant. These models are commercially available from various sources and are sequence-verified to ensure accuracy. They are essential for studying the molecular consequences of ZIC2 mutations in a controlled genetic background.

Knockout and knock-in lines are used to validate the function of ZIC2 in SHH signaling. For example, ZIC2 knockout cells show altered GLI1 expression, confirming its role as a modulator. These lines can be used in high-throughput screens to identify genetic modifiers.

Isogenic pairs (wild-type vs. ZIC2 mutant) can be used to screen for compounds that rescue SHH signaling defects. They are also useful for testing drugs targeting the SHH pathway, such as SMO inhibitors, and for studying resistance mechanisms.

CRISPR synthetic lethality screens can identify genes that are essential in ZIC2-mutant cells but not wild-type, revealing potential therapeutic targets. These screens can also identify biomarkers for patient stratification.